These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18043911)

  • 21. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
    Ververs FF; Voorbij HA; Zwarts P; Belitser SV; Egberts TC; Visser GH; Schobben AF
    Clin Pharmacokinet; 2009; 48(10):677-83. PubMed ID: 19743889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine.
    Onalan O; Cumurcu BE; Bekar L
    Mayo Clin Proc; 2008 May; 83(5):595-9. PubMed ID: 18452693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction.
    Everts B; Karlson BW; Herlitz J; Abdon NJ; Hedner T
    Eur J Clin Pharmacol; 1997; 53(1):23-31. PubMed ID: 9349926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interactions between metoprolol and antidepressants].
    Molden E; Spigset O
    Tidsskr Nor Laegeforen; 2011 Sep; 131(18):1777-9. PubMed ID: 21946596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.
    Bahar MA; Wang Y; Bos JHJ; Wilffert B; Hak E
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):621-629. PubMed ID: 29575226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine.
    Mikami A; Ohtani H; Hori S; Sawada Y
    Int J Clin Pharmacol Ther; 2013 May; 51(5):374-82. PubMed ID: 23357843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.
    Nozawa T; Taguchi M; Tahara K; Hashimoto Y; Igarashi N; Nonomura M; Kato B; Igawa A; Inoue H
    J Cardiovasc Pharmacol; 2005 Nov; 46(5):713-20. PubMed ID: 16220080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.
    Bahar MA; Hak E; Bos JHJ; Borgsteede SD; Wilffert B
    Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):752-765. PubMed ID: 28345306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].
    Fux R; Meisner C; Schwab M; Lorenz G; Mörike K; Gleiter CH
    Z Arztl Fortbild Qualitatssich; 2004 Nov; 98(8):689-94. PubMed ID: 15646732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.
    Taguchi M; Nozawa T; Kameyama T; Inoue H; Takesono C; Mizukami A; Hashimoto Y
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):385-8. PubMed ID: 12915955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
    Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
    Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.
    Koytchev R; Alken RG; Vlahov V; Kirkov V; Kaneva R; Thyroff-Friesinger U; Rehak E
    Eur J Clin Pharmacol; 1998 Aug; 54(6):469-74. PubMed ID: 9776437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
    Blake CM; Kharasch ED; Schwab M; Nagele P
    Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.
    Jin SK; Chung HJ; Chung MW; Kim JI; Kang JH; Woo SW; Bang S; Lee SH; Lee HJ; Roh J
    J Clin Pharm Ther; 2008 Oct; 33(5):567-73. PubMed ID: 18834373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
    Ismail R; Teh LK
    J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo.
    Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M
    Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent.
    Thürmann PA; Haack S; Werner U; Szymanski J; Haase G; Drewelow B; Reimann IR; Hippius M; Siegmund W; May K; Hasford J
    Clin Pharmacol Ther; 2006 Nov; 80(5):551-3. PubMed ID: 17112812
    [No Abstract]   [Full Text] [Related]  

  • 40. Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction.
    Shin J; Hills NK; Finley PR
    Pharmacotherapy; 2020 Jun; 40(6):507-516. PubMed ID: 32342526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.